Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
Annual influenza epidemics continue to have a considerable impact in both developed and developing countries. Vaccination remains the principal measure to prevent seasonal influenza and reduce associated morbidity and mortality. The WHO recommends using established mammalian cell culture lines as an alternative to egg-based substrates in the manufacture of influenza vaccine. In June 2007, the EMEA approved Optaflu, a Madin Darby canine kidney cell culture-derived influenza vaccine manufactured by Novartis Vaccines. This review examines the advantages and disadvantages of cell culture-based technology for influenza vaccine production, compares immunogenicity and safety data for Optaflu with that of currently marketed conventional egg-based influenza vaccines, and considers the prospects for wider use of cell culture-based influenza vaccines.
Doroshenko
Alexander
A
Canadian Center for Vaccinology, Departments of Pediatrics, Dalhousie University & IWK Health Centre, Halifax, Nova Scotia, Canada.
Halperin
Scott A
SA
D000818:Animals; D002460:Cell Line; D004285:Dogs; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects* / Q000276:immunology*; D009975:Orthomyxoviridae / Q000254:growth & development* / Q000276:immunology*
D007252:Influenza Vaccines